|
The convergence of diagnostics and therapeutics is steadily redefining standard care pathways by enabling precise, timely, and personalized clinical decision-making. There is a decisive shift from reactive care to evidence-led and diagnostics-first decision-making, said Dr Anand K, managing director & CEO, Agilus Diagnostics.
The development of precise medicines based on individual genetic and lifestyle information is resulting in effective interventions in oncology and chronic illnesses. Particularly genomics moved from being a niche capability to a clinically relevant tool, influencing both risk stratification and therapy selection, he added.
Artificial-intelligence-based systems eased operations, including diagnostic assistance and paperwork, improving the accuracy and speed of the functions. AI-driven imaging, pathology and clinical decision-support tools increasingly complemented physician judgment, enabling earlier and more confident diagnoses. Telehealth improved accessibility, especially in remote regions, whereas wearable gadgets increased real-time health tracking for preventive care. Clinicians observed that timely screenings and longitudinal data could meaningfully alter disease trajectories, particularly for diabetes, cardiovascular conditions and cancer, he noted.
Online technologies, including telemedicine services, provides accessibility in underserved areas. Biohacking and direct-to-consumer testing became widespread, encouraging personal health management. While these empowered patients, they also underscored the need for clinically validated diagnostics and physician-guided interpretation. In diagnostics, genomics and next generation technologies, personal therapies optimise the results by matching the treatment with the genetic profiles, said Dr Anand.
However, several challenges remained evident. Infrastructure shortages with limited beds, workforce issues, including clinician frustration from commoditisation and flat wages, which led to higher turnover and affected service consistency. From within the system, the pressure on doctors and diagnostic teams is visible, with rising caseloads and administrative burden impacting both morale and quality of care. The increasing costs, insurance rejections and resulted in patient dissatisfaction affecting trust and implementation, he pointed out.
Private investments played a role in addressing capacity, funding expansions in infrastructure and service quality. Government programmes focused on training and policies were aimed at including care into universal coverage schemes. However, its impact will depend on strengthening diagnostic infrastructure at the primary and secondary care levels, said Dr Anand.
This year, diagnostics will increasingly anchor clinical workflows, with AI-enabled labs, genomics-led screening and population health analytics shaping earlier interventions rather than late-stage treatment. Innovations in pharmaceuticals, including use of GLP-1 medications, will provide real-world evidence on the safety and novel use, which will affect the choice of treatment, he said.
Additionally, digital health transactions such as IPOs (initial public offers) will grow to promote innovations in fields such as virtual reality in therapy. Health equity initiatives might start being refocused, and high-need populations should be prioritised to enhance the overall performance of the system. For clinicians, this period will demand a balance between innovation and ethical responsibility, ensuring that technology enhances outcomes rather than widening care gaps.
Embedding preventive diagnostics and genomics into these programmes can reduce long-term disease burden. These can help ease systemic pressures and improve sustainability. As we move ahead, the healthcare sector must transition from treating illness to predicting and preventing it, placing diagnostics, genomics and early intervention at the core of care delivery, said Dr Anand.
|